Euroapi: production suspended in Brindisi
This Italian site produces 11 APIs (active pharmaceutical ingredients) and intermediates, mainly anti-infectives. In 2023, sales from Brindisi amounted to 63 million euros, 43% of which were generated with Sanofi.
The value of Brindisi's non-current assets has been fully impaired in the 2023 consolidated financial statements. This situation is expected to impact the Group's operating and financial performance. Consequently, the 2024 outlook is suspended.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction